You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

evoclin Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Evoclin, and what generic alternatives are available?

Evoclin is a drug marketed by Norvium Bioscience and is included in one NDA. There are two patents protecting this drug.

This drug has thirty patent family members in fifteen countries.

The generic ingredient in EVOCLIN is clindamycin phosphate. There are fifty-five drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the clindamycin phosphate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Evoclin

A generic version of evoclin was approved as clindamycin phosphate by ALMAJECT on July 24th, 1987.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for evoclin?
  • What are the global sales for evoclin?
  • What is Average Wholesale Price for evoclin?
Summary for evoclin
International Patents:30
US Patents:2
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 57
Drug Prices: Drug price information for evoclin
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for evoclin
What excipients (inactive ingredients) are in evoclin?evoclin excipients list
DailyMed Link:evoclin at DailyMed
Drug patent expirations by year for evoclin
Drug Prices for evoclin

See drug prices for evoclin

US Patents and Regulatory Information for evoclin

evoclin is protected by two US patents.

Patents protecting evoclin

Pharmaceutical foam
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Pharmaceutical foam
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ACNE VULGARIS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Norvium Bioscience EVOCLIN clindamycin phosphate AEROSOL, FOAM;TOPICAL 050801-001 Oct 22, 2004 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Norvium Bioscience EVOCLIN clindamycin phosphate AEROSOL, FOAM;TOPICAL 050801-001 Oct 22, 2004 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for evoclin

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Norvium Bioscience EVOCLIN clindamycin phosphate AEROSOL, FOAM;TOPICAL 050801-001 Oct 22, 2004 ⤷  Sign Up ⤷  Sign Up
Norvium Bioscience EVOCLIN clindamycin phosphate AEROSOL, FOAM;TOPICAL 050801-001 Oct 22, 2004 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for evoclin

See the table below for patents covering evoclin around the world.

Country Patent Number Title Estimated Expiration
Norway 339620 ⤷  Sign Up
Eurasian Patent Organization 014372 ПЕНА НА ОСНОВЕ ФОСФАТА КЛИНДАМИЦИНА (CLINDAMYCIN PHOSPHATE FOAM) ⤷  Sign Up
Spain 2637956 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2004064833 ⤷  Sign Up
Eurasian Patent Organization 009031 ПЕНА НА ОСНОВЕ ФОСФАТА КЛИНДАМИЦИНА (CLINDAMYCIN PHOSPHATE BASED FOAM) ⤷  Sign Up
Eurasian Patent Organization 200701259 ПЕНА НА ОСНОВЕ ФОСФАТА КЛИНДАМИЦИНА ⤷  Sign Up
European Patent Office 1592420 MOUSSE DE PHOSPHATE DE CLINDAMYCINE (CLINDAMYCIN PHOSPHATE FOAM) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for evoclin

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1304992 C300617 Netherlands ⤷  Sign Up PRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
1304992 122013000081 Germany ⤷  Sign Up PRODUCT NAME: CLINDAMYCIN (ALS CLINDAMYCIN-PHOSPHAT) UND TRETINOIN; NAT. REGISTRATION NO/DATE: 85210.00.00 20130611; FIRST REGISTRATION: IRLAND PA1332/043/001 20130322
1304992 2013C/060 Belgium ⤷  Sign Up PRODUCT NAME: CLINDAMYCINE (ALS CLINDAMYCINE FOSFAAT) EN TRETINOINE; AUTHORISATION NUMBER AND DATE: BE437507 20130506
1304992 2013/044 Ireland ⤷  Sign Up PRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322
1304992 CR 2013 00053 Denmark ⤷  Sign Up PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
1304992 SPC/GB13/061 United Kingdom ⤷  Sign Up PRODUCT NAME: CLINDAMYCIN PHOSPHATE IN COMBINATION WITH TRETINOIN.; REGISTERED: IE PA1332/043/001 20130322; UK PL15142/0249 20130624
1304992 PA2013025,C1304992 Lithuania ⤷  Sign Up PRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.